Group 1 - The company signed a technology transfer contract with Nanjing Gulou Hospital for the transfer of technical secrets related to NK cell-specific antigens and tumor-specific antigen cell connectors, with a total contract amount of 78.5 million yuan (including tax) [6][10] - The payment structure includes an upfront fee of 1.5 million yuan, progress rewards totaling 2.5 million yuan, and sales sharing up to 74.5 million yuan based on future sales [10][11] - The transaction is not classified as a related party transaction and does not constitute a major asset restructuring as per relevant regulations [6][7] Group 2 - The technology involved aims to enhance the targeting ability of NK cells against tumors without the need for transfection, which is a significant advancement in biomedicine [9] - The contract allows the company to develop, produce, and sell products based on the transferred technology globally and indefinitely [13] - The company anticipates that this transaction will help expand its pipeline in the biopharmaceutical sector, aligning with its long-term strategic goals [17] Group 3 - The company held a board meeting on October 24, 2025, where it approved the signing of the technology transfer contract [6][20] - The company plans to revise its articles of association and related meeting rules, including the cancellation of the supervisory board, which will be replaced by the audit committee of the board [20][21] - The proposed changes to the articles of association and meeting rules will be submitted for approval at the upcoming third extraordinary general meeting of shareholders [20]